compound introduction
YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor with an IC 50 of 2.12 nM/1.40 nM/2.86 nM for SIK1 , SIK2 and SIK3 , respectively. In Vitro YKL 06-062 (0.0004-16 μM; 3 hours) increases MITF mRNA expression in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: Human melanocyte cells, UACC62 melanoma cells Concentration: 0.0004 μM, 0.004 μM, 0.04 μM, 0.4 μM, 4 μM,8 μM,16 μM Incubation Time: 3 hours Result: Unregulated MITF mRNA expression. Form:Solid
